Dayvigo Food & Supplement Interactions: What to Avoid With Lemborexant

How Lemborexant Works: The Mechanism Behind Dayvigo

Lemborexant blocks both orexin receptor subtypes OX1R and OX2R. Orexin A and orexin B are wake-promoting neuropeptides; when lemborexant occupies those receptors, the brain's arousal drive is suppressed and sleep onset follows. This is fundamentally different from benzodiazepines or Z-drugs, which act on GABA-A receptors.

Understanding the mechanism matters for interactions because it tells you which pharmacodynamic pathways overlap with food and supplements.

The Orexin System and Sleep

The orexin system originates in the lateral hypothalamus. Orexin neurons project widely to the locus coeruleus, dorsal raphe, tuberomammillary nucleus, and basal forebrain, all regions that sustain wakefulness [1]. Antagonizing both receptor subtypes simultaneously produces what the pharmacology literature calls "dual orexin receptor antagonism" (DORA), the same class mechanism as suvorexant (Belsomra), though lemborexant has a distinct receptor-binding profile and faster offset kinetics [2].

Why CYP3A4 Dominates the Interaction Profile

After oral dosing, lemborexant is absorbed and then metabolized in the liver and intestinal wall by CYP3A4. The FDA pharmacology review notes that a strong CYP3A4 inhibitor (itraconazole 200 mg daily) increased lemborexant area-under-the-curve (AUC) by approximately 3.8-fold [3]. A 3.8-fold AUC increase at the 10 mg dose is equivalent to taking nearly 38 mg from a pure-exposure standpoint, far above any studied dose. That single datum explains why the label prohibits co-administration with strong inhibitors and why even moderate inhibitors (including grapefruit juice) deserve serious attention.

Grapefruit and Grapefruit Juice

Avoid grapefruit in all forms while taking lemborexant. This is a concrete, non-negotiable instruction from the FDA-approved prescribing information, not a theoretical caution [3].

Why Grapefruit Is a Problem

Grapefruit contains furanocoumarins, mainly bergamottin and 6',7'-dihydroxybergamottin, that irreversibly inhibit CYP3A4 in the gut wall [4]. Because lemborexant relies on intestinal CYP3A4 for first-pass metabolism, a single 200 mL glass of grapefruit juice can reduce pre-systemic clearance enough to substantially increase peak plasma concentration (Cmax) and AUC. The inhibition persists for up to 72 hours after ingestion, so skipping grapefruit "just on dosing days" is not a workable strategy [4].

What "All Forms" Means in Practice

Whole grapefruit, grapefruit juice (including "not from concentrate" varieties), grapefruit segments in fruit salads, and Seville oranges (used in some marmalades) all contain relevant furanocoumarin levels. Tangelo, a grapefruit-tangerine hybrid, carries the same risk. Regular navel oranges, blood oranges, and clementines are safe.

Alcohol and Lemborexant

Alcohol should be avoided on nights when lemborexant is taken. The two substances produce additive CNS depression through overlapping but mechanistically distinct pathways.

Pharmacodynamic Overlap

Lemborexant suppresses arousal signaling. Alcohol depresses CNS activity through GABA-A potentiation and NMDA receptor inhibition [5]. The combined effect is not simply "feeling sleepier." It means greater respiratory depression risk, longer time to full awakening if stimulated during the night, and meaningfully prolonged next-morning psychomotor impairment.

Evidence From the Lemborexant Development Program

The SUNRISE-2 phase 3 trial (N=949, 12 months) excluded patients with current alcohol use disorder and tracked next-morning function using the Karolinska Sleepiness Scale and Digit Symbol Substitution Test [6]. Even without alcohol co-use, lemborexant 10 mg produced residual sleepiness in a subset of patients on morning-after assessments. Adding even two standard drinks to 10 mg lemborexant would be expected to amplify that impairment substantially, though the specific combination has not been studied in a dedicated interaction trial.

Practical Guidance for Patients

One glass of wine at dinner followed by lemborexant at 10 pm carries real risk, particularly for driving the next morning. Patients who work early shifts or operate machinery should be specifically counseled that the interaction is pharmacodynamic, not pharmacokinetic, meaning no dose adjustment eliminates the problem.

Melatonin

Melatonin is the most commonly used sleep supplement in the United States, with approximately 3.1 million U.S. Adults using it regularly according to the 2012 National Health Interview Survey [7]. Many patients starting lemborexant are already taking melatonin nightly.

No Pharmacokinetic Interaction

Melatonin is metabolized primarily by CYP1A2, not CYP3A4, so it does not alter lemborexant plasma levels and lemborexant does not alter melatonin levels [8]. From a pure PK standpoint, the combination is neutral.

The Pharmacodynamic Concern

Both agents promote sleep onset through different mechanisms, but the resulting sedation is additive. Patients taking 10 mg melatonin (well above the 0.5 mg physiological dose) alongside 10 mg lemborexant may experience difficulty waking for nighttime emergencies and prolonged next-morning grogginess. The American Academy of Sleep Medicine 2017 clinical practice guideline notes that evidence supporting melatonin for chronic insomnia disorder is weak (GRADE: weak recommendation, very low-quality evidence), suggesting patients might reasonably discontinue melatonin when starting a prescription DORA rather than layering them [9].

Recommendation

Prescribers should review melatonin dose and timing at the first appointment. Doses above 1 mg taken simultaneously with lemborexant warrant either stopping melatonin or starting lemborexant at the 5 mg dose.

Valerian Root

Valerian (Valeriana officinalis) is a widely available herbal supplement marketed for sleep. Its active constituents include valerenic acid and isovaleric acid, which appear to modulate GABA-A receptors and may weakly inhibit GABA transaminase [10].

CYP Interaction Data

In vitro data suggest valerian extracts may inhibit CYP3A4 at high concentrations, though clinically meaningful inhibition at typical supplement doses has not been confirmed in a dedicated human PK study [10]. Prescribers cannot rule out a modest increase in lemborexant exposure, particularly with standardized high-potency extracts.

CNS Depression Overlap

Valerenic acid's GABAergic activity adds a pharmacodynamic sedation layer on top of lemborexant's orexin blockade. The magnitude is uncertain because valerian products vary widely in valerenic acid content, sometimes by more than 10-fold across commercial preparations [10].

Clinical Guidance

Patients should disclose valerian use at intake. If they wish to continue, starting lemborexant at 5 mg and reassessing next-morning function at two weeks is a reasonable clinical approach.

Kava

Kava (Piper methysticum) is used in Pacific Island cultures as a ceremonial beverage and sold globally as a supplement for anxiety and sleep. Avoid it during lemborexant therapy for two reasons.

Hepatotoxicity Risk

The FDA issued a consumer advisory on kava-associated liver injury in 2002, citing cases of hepatitis, cirrhosis, and liver failure [11]. Because lemborexant is hepatically cleared, any impairment of liver function changes its metabolic handling unpredictably.

CNS Depression

Kavalactones inhibit voltage-gated sodium and calcium channels and potentiate GABA-A activity, producing sedation that compounds lemborexant's effect [12]. The combination has not been studied; given the hepatotoxicity signal, no clinical trial is likely to study it prospectively.

Cannabidiol (CBD)

CBD has gained significant consumer popularity as a sleep aid. It is available over the counter in most U.S. States despite ambiguous regulatory status for dietary supplement claims.

CYP3A4 Inhibition by CBD

CBD is a moderate inhibitor of CYP3A4 in vitro, and clinical data from the antiepileptic literature confirm that CBD 750 mg twice daily increased clobazam AUC by approximately 60% in patients with Dravet syndrome [13]. CBD products marketed for sleep typically deliver 25 to 75 mg per dose, lower than antiepileptic doses, but the inhibitory potential is not zero at these amounts.

Practical Implication

A patient taking 50 mg CBD oil nightly alongside 10 mg lemborexant may experience a modest CYP3A4-mediated rise in lemborexant exposure. The prescriber should know about CBD use and may elect to start or remain at 5 mg lemborexant in those patients.

Strong CYP3A4 Inhibitors: Prescription Drugs That Matter

Several prescription and over-the-counter drugs inhibit CYP3A4 strongly enough to make lemborexant co-administration contraindicated per FDA labeling [3].

Contraindicated Agents

Strong inhibitors that appear on the FDA-defined list and interact with lemborexant include itraconazole, ketoconazole, clarithromycin, ritonavir, and cobicistat-containing antiretroviral regimens. The itraconazole interaction study showing 3.8-fold AUC increase is the anchor data point [3]. For patients who need antifungal therapy, fluconazole (a moderate inhibitor) requires dose reduction of lemborexant to 5 mg rather than outright avoidance, per the prescribing information.

Moderate Inhibitors: Dose-Reduction Zone

Moderate CYP3A4 inhibitors, including fluconazole, diltiazem, verapamil, and erythromycin, increase lemborexant exposure approximately 1.5 to 3-fold. The label recommends reducing lemborexant to 5 mg and monitoring for excess sedation [3].

Strong CYP3A4 Inducers

Strong inducers accelerate lemborexant metabolism, potentially dropping plasma levels below therapeutic range.

Rifampin as the Index Compound

Rifampin is the reference inducer used in FDA drug interaction guidance. In lemborexant's clinical pharmacology program, co-administration with a strong inducer reduced lemborexant AUC by approximately 88% [3]. At that degree of exposure reduction, the 5 mg or 10 mg dose is unlikely to provide meaningful sleep benefit.

Other Inducers to Know

Carbamazepine, phenytoin, St. John's Wort (Hypericum perforatum), and rifabutin are all strong-to-moderate CYP3A4 inducers. St. John's Wort is particularly relevant because patients often take it for mood support alongside sleep aids without disclosing it as a "supplement" rather than a drug [14]. Prescribers should ask specifically about St. John's Wort by name.

St. John's Wort: A Special Case

St. John's Wort deserves its own section because it sits at the intersection of supplement use, psychiatric co-morbidity, and CYP3A4 induction.

Mechanism of Induction

The active constituent hyperforin activates the pregnane X receptor (PXR), which transcriptionally up-regulates CYP3A4 and P-glycoprotein expression in the liver and intestine [14]. Effects accumulate over 2 weeks of daily use and persist for roughly 1 week after discontinuation.

Clinical Consequence With Lemborexant

A patient stabilized on lemborexant 10 mg who starts St. John's Wort will likely find their insomnia returning over 2 to 4 weeks as CYP3A4 induction reduces their plasma lemborexant levels. The prescriber might incorrectly interpret this as tolerance rather than an herb-drug interaction.

The HealthRX clinical review team has developed the following three-tier disclosure framework for supplement review at lemborexant initiation visits:

Tier 1, Stop before starting (contraindicated or hepatotoxic): Kava, strong CYP3A4 inhibitor supplements (e.g., high-dose CBD above 100 mg/day), grapefruit-seed extract.

Tier 2, Dose-adjust or switch lemborexant to 5 mg: Moderate CBD doses (25 to 75 mg/day), valerian standardized extracts, melatonin above 1 mg, ginger root in therapeutic doses (CYP3A4 weak inhibition reported in vitro).

Tier 3, Disclose and monitor: Melatonin 0.5 to 1 mg, chamomile tea, passionflower, magnesium glycinate. These have no identified CYP3A4 interaction and low pharmacodynamic overlap, but patients should report any unusual morning sedation.

High-Fat Meals and Lemborexant Absorption

High-fat meals delay lemborexant's time to peak concentration (Tmax) but do not materially change total exposure (AUC) [3]. This is clinically important.

What "Delayed Tmax" Means Practically

In fed-state pharmacokinetic studies, a high-fat meal pushed lemborexant Tmax from approximately 1 to 2 hours (fasted) to approximately 3 hours (fed) [3]. For a patient who takes lemborexant at 10 pm after a large dinner, peak sedation may not arrive until 1 am rather than 11 pm, which could leave them awake longer than expected before drug effect is felt.

The Label Instruction

The FDA prescribing information states lemborexant should be taken immediately before bed regardless of food. Patients with delayed gastric emptying (e.g., those with gastroparesis or taking GLP-1 receptor agonists) may experience even longer delays in onset. This is not a safety risk but is a compliance risk if patients conclude "the pill isn't working" and take a second dose.

The SUNRISE-1 Trial: Efficacy Context for Interaction Counseling

Understanding that lemborexant's benefit-risk ratio depends on achieving therapeutic exposure makes interaction counseling directly relevant to efficacy, not just safety.

SUNRISE-1 Design and Results

SUNRISE-1 was a 4-week phase 3 randomized controlled trial (N=291 adults with insomnia disorder) comparing lemborexant 5 mg, lemborexant 10 mg, zolpidem ER 6.25 mg, and placebo. Published in JAMA Network Open (2019), the trial showed lemborexant 10 mg reduced latency to persistent sleep (LPS) by a mean of 16 minutes versus placebo (P<0.001) and produced better next-morning function scores than zolpidem ER on the DSST at month 1 [15]. The 5 mg dose showed meaningful LPS reduction with an even more favorable next-morning profile.

Why This Matters for Interactions

A patient who co-uses a strong CYP3A4 inducer like rifampin or St. John's Wort may lose the 16-minute LPS benefit entirely as plasma levels fall. Conversely, a patient who adds itraconazole to a stable 10 mg lemborexant regimen may experience next-morning sedation, impaired driving, and respiratory risks at a supratherapeutic effective dose.

Next-Morning Driving and Compound Sedation

The FDA required a dedicated next-morning driving study for lemborexant before approval. The study used a standardized deviation of lateral position (SDLP) road-tracking test at 9 hours post-dose.

The Driving Study Findings

At lemborexant 10 mg, SDLP the morning after dosing was statistically worse than placebo but less impaired than zolpidem ER 6.25 mg [3]. The prescribing information carries a warning that next-morning driving impairment is possible and that patients should not drive or operate machinery until they feel fully alert.

Compounding Factors

Alcohol, melatonin above physiological doses, and CNS-depressant supplements all worsen SDLP beyond what lemborexant alone produces. Any interaction that raises lemborexant plasma levels (grapefruit, strong CYP3A4 inhibitors) also extends the duration of impaired driving risk into the following morning. Patients who must drive before 8 am after a 10 pm dose are at particular risk if they have consumed any of these interacting substances.

Renal and Hepatic Impairment: How Disease State Changes Interaction Risk

Organ impairment is not a food or supplement interaction, but it changes the baseline from which food and supplement interactions operate.

Hepatic Impairment

Severe hepatic impairment (Child-Pugh C) is a contraindication to lemborexant because CYP3A4 capacity is reduced, and the drug accumulates [3]. Patients with moderate hepatic impairment (Child-Pugh B) should not exceed 5 mg. Any CYP3A4 inhibiting supplement (CBD, valerian, grapefruit) further reduces metabolic clearance in these patients, making even 5 mg potentially supratherapeutic.

Renal Impairment

No dose adjustment is required for mild-to-severe renal impairment or end-stage renal disease based on the population PK analysis submitted to the FDA [3]. Food and supplement interactions are not modified by renal status alone.